Emmanuelle Coutanceau
Investment Manager @ Omnes Capital
Copenhagen, Denmark
Emmanuelle Coutanceau is a Series A investor at Omnes Capital in Copenhagen focused on Biotechnology and Health Care. Emmanuelle Coutanceau joined Omnes Capital's Venture Capital team in April 2007.She holds a degree in agronomic engineering from the ENSAR in Rennes, a PhD in Microbiology from Paris VII University and a specialized postgraduate degree in pharmaceutical management from the Paris ESCP-EAP Business School.From 2003 to 2006, at PasteurInstitute, Emmanuelle Coutanceau managed a fundamental research project on the immunosuppressive properties of a bacterial toxin. Her work led to several international scientific publications. In Omnes Capital, she has been actively involved in several investments. She currently serves as director on the board of Amakem, Complix, Arcarios and as observer on the board of FlexGen, Medisse, ERA Biotech and Complix.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Emmanuelle Coutanceau invests in
Stages Emmanuelle Coutanceau invests in
Countries Emmanuelle Coutanceau invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (60%)
- Health Care 3 (30%)
- Medical 2 (20%)
- Life Science 2 (20%)
- Therapeutics 2 (20%)
Stage
- Series A 5 (50%)
- Series B 2 (20%)
- Grant 1 (10%)
- Series C 1 (10%)
- Funding Round 1 (10%)
Country
- Belgium 3 (30%)
- France 2 (20%)
- Denmark 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M / Series A / Mar 24, 2025 | ||
| Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases. | $32.9M / Series A / Jan 09, 2025 | ||
| Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M / Series C / Dec 15, 2022 | ||
| Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $57.6M / Series B / Dec 15, 2020 | ||
| Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $5M / Grant / Jan 21, 2019 | ||
| Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to itsouter membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria. | $2.7M / Mar 18, 2015 | ||
| Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to itsouter membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria. | $2.1M / Series A / Dec 01, 2014 | ||
| Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins. | $13.2M / Series B / Jun 26, 2013 | ||
| Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducingside effects. | $19.7M / Series A / Sep 06, 2011 | ||
| Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins. | $2.2M / Series A |
Co-Investors
About Omnes Capital
Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.
Omnes Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Fabien Collangettes
Partner
|
|||
Fabien Prevost
CEO
|
|||
Laurent Perret
Principal & Director of investments
|
|||
Michael Pollan
Investment Director, Renewable Energy
|
|||
Pierre-Axel Botuha
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Emmanuelle Coutanceau invest in?
Emmanuelle Coutanceau invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Emmanuelle Coutanceau?
Public channels for Emmanuelle Coutanceau include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Emmanuelle Coutanceau last invest?
The most recent investment recorded for Emmanuelle Coutanceau closed in Mar 2025. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
